Fiera Capital Corp Sells 38,574 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fiera Capital Corp decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 23.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 125,735 shares of the company’s stock after selling 38,574 shares during the period. Fiera Capital Corp owned about 0.15% of IDEXX Laboratories worth $63,524,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of IDXX. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories in the first quarter worth approximately $26,000. Ridgewood Investments LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth $27,000. Institutional & Family Asset Management LLC bought a new stake in IDEXX Laboratories during the second quarter valued at about $28,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC grew its position in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Down 0.6 %

Shares of IDEXX Laboratories stock traded down $2.50 during trading on Friday, hitting $430.50. The stock had a trading volume of 145,130 shares, compared to its average volume of 496,252. The stock has a market cap of $35.25 billion, a PE ratio of 41.35, a PEG ratio of 3.61 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $404.74 and a 12 month high of $583.39. The firm’s fifty day simple moving average is $474.87 and its 200-day simple moving average is $485.88. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the previous year, the business earned $2.53 earnings per share. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research analyst reports. BTIG Research initiated coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday. Piper Sandler reissued a “neutral” rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Finally, JPMorgan Chase & Co. decreased their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.